Literature DB >> 21198260

APEX1 Asp148Glu gene polymorphism is a risk factor for lung cancer in relation to smoking in Japanese.

Kayo Osawa1, Aiko Miyaishi, Kazuya Uchino, Yasunori Osawa, Natsuko Inoue, Chiaki Nakarai, Akimitsu Tsutou, Yoshiaki Kido, Masahiro Yoshimura, Noriaki Tsubota, Juro Takahashi.   

Abstract

DNA repair enzymes play an important role in the development of various kinds of cancer. We here analyzed associations of XPD Lys751Gln, APEX1 Asp148Glu, XRCC1 Arg399Gln, and XRCC3 Thr241Met gene polymorphisms in DNA repair pathways in relation to the risk of lung cancer using PCR-RFLP. The study involved 104 lung cancer patients and 120 non-cancer controls divided into non-smokers and smokers. We found a statistically significant interaction between APEX1 Asp148Glu and the risk for lung cancer (adjusted OR 2.78, 95% CI 1.58-4.90, p=0.0004), of both adenocarcinoma (adjusted OR 2.24, 95%CI 1.18-4.25, p=0.014) and squamous cell carcinoma (adjusted OR 4.75, 95%CI 1.79-12.6, p=0.002) types. XRCC1 Arg399Gln showed a borderline significant association with adenocarcinoma (adjusted OR 1.89, 95%CI 1.00-3.57, p=0.051). The combined effect of smoking and presence of the APEX1 Asp148Glu demonstrated a significant association with risk of lung cancer (adjusted OR 3.61, 95% CI 1.74-7.50, p=0.001). The XPD Lys751Gln and XRCC3 Thr241Met genotypes displayed no statistically significant risk. Our findings suggest that the APEX1 Asp148Glu is associated with increased risk for primary lung cancer in Japanese individuals partaking in smoking.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21198260

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

1.  XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case-control studies.

Authors:  Liping Dai; Fujiao Duan; Peng Wang; Chunhua Song; Kaijuan Wang; Jianying Zhang
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis.

Authors:  Wenlong Zhai; Ruo Feng; Haiyu Wang; Yadong Wang
Journal:  Tumour Biol       Date:  2015-04-03

3.  The association of APE1 Asp148Glu gene polymorphisms and lung cancer risk: an updated meta-analysis.

Authors:  Wen Chen; Qin Wang; Mang Liu; Xiao-bing Ding
Journal:  Tumour Biol       Date:  2013-12-06

4.  Genetic polymorphism of APE1 rs1130409 can contribute to the risk of lung cancer.

Authors:  Feng Jin; Chengyuan Qian; Yi Qing; Zhimin Zhang; Ge Wang; Jinlu Shan; Nan Dai; Zheng Li; Dong Wang
Journal:  Tumour Biol       Date:  2014-04-06

5.  APE1 Asp148Glu polymorphism and lung cancer susceptibility.

Authors:  Liyun Cai; Yingjv Fu; Yuanyue Zhang
Journal:  Tumour Biol       Date:  2014-02-13

6.  Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Wu Wei; Xiao-Feng He; Jiang-Bo Qin; Jiao Su; Shao-Xia Li; Yi Liu; Ying Zhang; Wei Wang
Journal:  Mol Biol Rep       Date:  2012-10-12       Impact factor: 2.316

7.  Lack of association between XRCC3 rs861539 (C > T) polymorphism and lung cancer risks: an update meta-analysis.

Authors:  Chun-Lei Shi; Rong Li; Li-Wen Xiong; Ai-Qin Gu; Bao-Hui Han; Wei Gu
Journal:  Tumour Biol       Date:  2013-03-26

8.  X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis.

Authors:  Ji-Ying Wang; Yong Cai
Journal:  Tumour Biol       Date:  2013-08-14

9.  XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Ping Zhan; Qin Wang; Qian Qian; Li-Ke Yu
Journal:  J Exp Clin Cancer Res       Date:  2013-01-04

10.  XRCC3 gene polymorphism is associated with survival in Japanese lung cancer patients.

Authors:  Kayo Osawa; Chiaki Nakarai; Kazuya Uchino; Masahiro Yoshimura; Noriaki Tsubota; Juro Takahashi; Yoshiaki Kido
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.